Nirmatrelvir-ritonavir significantly reduces severe COVID-19 outcomes in diverse Taiwanese populations: Comprehensive evidence from a large-scale longitudinal cohort study in Taiwan
Fu‐Der Wang(Taipei Veterans General Hospital), Jason C. Hsu(Taipei Medical University Hospital), Chieh Yang(Taipei Medical University), Tsong‐Yih Ou(Taipei Medical University Hospital), Han-Chuan Chuang(Taipei Medical University Hospital), Min‐Huei Hsu(Taipei Medical University Hospital), Y. W. Chang(Taipei Medical University), Shiue-Ming Lin(Taipei Medical University), Mei-Hui Lee(Taipei Medical University-Shuang Ho Hospital), Phung-Anh Nguyen(Taipei Medical University Hospital), Whitney Burton(Taipei Medical University)
Cited by 0
Related Papers
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
|DOAJ (DOAJ: Directory of Open Access Journals)|2022|76
Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030.
|Journal of Infection and Public Health|2024|37
A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: an ecological study
|Frontiers in Public Health|2023|19